SFA Therapeutics is focused on developing next-generation drugs that target autoimmune diseases, chronic inflammatory conditions, and cancer by leveraging the complex interactions within the human gut microbiome. The company has identified biosynthetic molecules derived from bacterial metabolites that mimic naturally occurring substances in the body. This innovative approach allows for the creation of disease-specific drugs that enhance selectivity and specificity, ultimately leading to safer treatments with predictable outcomes. Their platform technology aims to harness these compounds to influence immune function and metabolism, addressing a range of health challenges, including psoriasis, liver cancer, and various ophthalmic diseases.

The therapeutic strategy employed by SFA Therapeutics emphasizes the use of small molecules that interact selectively with disease-specific targets while maintaining immune homeostasis. These compounds are designed to boost anti-inflammatory responses and downregulate pro-inflammatory cytokines, promoting a balanced immune response. By deriving drugs from endogenous substances, the company aims to minimize genotoxicity and expedite clinical development, ensuring a safer therapeutic profile. Their pipeline reflects a commitment to innovative oral formulations that promise consistent clinical outcomes, positioning SFA Therapeutics at the forefront of biopharmaceutical advancements in treating complex diseases.

United States

SFA Therapeutics is a clinical stage start-up biotech company developing compounds discovered in human microbiome. This patented and proprietary platform is based on immuno-modulation of inflammatory factors derived from human gut microbiome. The technology is licensed from and supported by research at Temple University in Philadelphia. These products are a unique native immunotherapy platform with activity currently being investigated in cancer, liver, and auto-immune disease.

SFA Therapeutics

Company Details